Design and Ultrasound Assisted Synthesis of Novel 1,3,4-Oxadiazole Drugs for Anti-Cancer Activity

被引:17
作者
Bhatt, Priyanka [1 ]
Sen, Anik [1 ]
Jha, Anjali [1 ]
机构
[1] Deemed Univ, GITAM, Inst Sci, Dept Chem, Visakhapatnam 530045, Andhra Pradesh, India
来源
CHEMISTRYSELECT | 2020年 / 5卷 / 11期
关键词
Anti-Cancer; Density Functional Calculations; Drug Design; Molecular Docking; MTT assay; Ultrasound synthesis; BIOLOGICAL EVALUATION; ANTITUMOR-ACTIVITY; CANCER; INHIBITORS; SCAFFOLD; DISCOVERY; KINASES; ANALOGS;
D O I
10.1002/slct.201904412
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
An ultrasound assisted multi-component synthesis of a series of 2-(N-heterocycle) substituted 1,3,4-oxadiazoles have been performed. A proper IR, UV, Mass and NMR spectral analysis supported the 12 synthesized novel compounds. Compound 5-bromo-1-((4-chlorophenyl)((5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)amino)methyl) indoline-2,3-dione (D8), displayed significant cytotoxicity against all the three human cancer cell lines studied in this article (breast cancer cell line MCF-7, colorectal cancer cell line HT-29 and liver cancer cell line Hep G2) using MTT assay. Further in silico target hunting using Chem Mapper led to the identification of two important cancer targets; EGFR and CDK2 kinases. Compound D8 was studied in detail using AutoDock and displayed high binding energies with the two proteins. Quantum chemical calculations of the designed compound D8 at the active site with specific amino acids for both the proteins showed stronger interactions at the active sites similar to the docking studies.
引用
收藏
页码:3347 / 3354
页数:8
相关论文
共 48 条
  • [1] Design and synthesis of new 2,5-disubstituted-1,3,4-oxadiazole analogues as anticancer agents
    Agarwal, Mohit
    Singh, Vikram
    Sharma, Sachin Kumar
    Sharma, Piush
    Ansari, Md. Yousuf
    Jadav, Surender Singh
    Yasmin, Sabina
    Sreenivasulu, Reddymasu
    Hassan, Mohd. Zaheen
    Saini, Vipin
    Ahsan, Mohamed Jawed
    [J]. MEDICINAL CHEMISTRY RESEARCH, 2016, 25 (10) : 2289 - 2303
  • [2] [Anonymous], 2017, WHO | Cancer Fact Sheet
  • [3] [Anonymous], RECENT RESULTS CANC
  • [4] [Anonymous], 2000, HDB HETEROCYCLIC CHE
  • [5] Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
    Bach, Peter B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (06) : 626 - 633
  • [6] 1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents
    Bajaj, Shalini
    Asati, Vivek
    Singh, Jagadish
    Roy, Partha Pratim
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 97 : 124 - 141
  • [7] Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity
    Bansal, Sumit
    Bala, Manju
    Suthar, Sharad Kumar
    Choudhary, Shivani
    Bhattacharya, Shoumyo
    Bhardwaj, Varun
    Singla, Sumit
    Joseph, Alex
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 80 : 167 - 174
  • [8] An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles
    Baumann, Marcus
    Baxendale, Ian R.
    [J]. BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY, 2013, 9 : 2265 - 2319
  • [9] Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues
    Beedie, Shaunna L.
    Peer, Cody J.
    Pisle, Steven
    Gardner, Erin R.
    Mahony, Chris
    Barnett, Shelby
    Ambrozak, Agnieszka
    Guetschow, Michael
    Chau, Cindy H.
    Vargesson, Neil
    Figg, William D.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (10) : 2228 - 2237
  • [10] Synthesis, docking and anticancer activity of azo-linked hybrids of 1,3,4-thia-/oxadiazoles with cyclic imides
    Bhatt, Priyanka
    Kumar, Manoj
    Jha, Anjali
    [J]. MOLECULAR DIVERSITY, 2018, 22 (04) : 827 - 840